Lack Of Response To Herceptin May Be Reversed With Addition Of A PI3K Inhibitor

... Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at The University of Texas M. D. Anderson Cancer Center.Their findings, reported at the annual meeting of the American Association for Cancer Research (AACR), were made in cell culture and mice studies, but are so promising that a Phase I/II clinical trial will start at M... click link for more info. ...